We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

89 hedge funds and large institutions have $249M invested in Aldeyra Therapeutics in 2018 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

288% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 8

247% more call options, than puts

Call options by funds: $1.98M | Put options by funds: $571K

158% more capital invested

Capital invested by funds: $96.4M → $249M (+$152M)

138% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 13

35% more funds holding

Funds holding: 66 → 89 (+23)

25.21% more ownership

Funds ownership: 60.33% → 85.54% (+25%)

Holders
89
Holders Change
+23
Holders Change %
+34.85%
% of All Funds
2.03%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
31
Increased
31
Reduced
13
Closed
8
Calls
$1.98M
Puts
$571K
Net Calls
+$1.41M
Net Calls Change
+$1.37M

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$8.27M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.73M
3
KCM
Knoll Capital Management
Florida
+$2.92M
4
6CM
683 Capital Management
New York
+$2.84M
5
EI
EAM Investors
California
+$2.53M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.91M
2
SLG
Stanley-Laman Group
Pennsylvania
-$786K
3
JP Morgan Chase
JP Morgan Chase
New York
-$455K
4
EIM
Essex Investment Management
Massachusetts
-$312K
5
PCM
Prelude Capital Management
New York
-$141K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$42.6M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$35.4M +$7.73M +953,022 +59%
6CM
3
683 Capital Management
New York
$18.6M +$2.84M +350,000 +35%
SFM
4
Sphera Funds Management
Israel
$15.8M +$2.39M +295,154 +35%
Citigroup
5
Citigroup
New York
$14.1M +$8.27M +1,018,934 +44,534%
Vanguard Group
6
Vanguard Group
Pennsylvania
$13.1M +$1.57M +193,707 +26%
Millennium Management
7
Millennium Management
New York
$13.1M +$1.8M +222,273 +31%
BlackRock
8
BlackRock
New York
$11M +$130K +16,044 +2%
MP
9
Mangrove Partners
Connecticut
$9.77M +$2.22M +273,402 +63%
KCM
10
Knoll Capital Management
Florida
$6.32M +$2.92M +360,000 +290%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$5.4M -$2.91M -359,000 -48%
EI
12
EAM Investors
California
$4.31M +$2.53M +312,092 New
State Street
13
State Street
Massachusetts
$3.41M +$82.5K +10,164 +4%
GGHC
14
Gilder Gagnon Howe & Co
New York
$3.01M +$1.77M +218,081 New
Northern Trust
15
Northern Trust
Illinois
$2.83M +$112K +13,807 +7%
CH
16
CVI Holdings
Delaware
$2.76M +$1.62M +200,000 New
LCM
17
Laurion Capital Management
New York
$2.76M +$1.62M +200,000 New
KC
18
Kepos Capital
New York
$2.61M – – –
WMSA
19
Weiss Multi-Strategy Advisers
New York
$2.55M +$1.17M +144,800 +360%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$2.16M +$69.8K +8,598 +6%
Russell Investments Group
21
Russell Investments Group
United Kingdom
$2.1M -$130K -15,964 -10%
SCM
22
Stonepine Capital Management
Oregon
$2M +$1.18M +145,000 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.79M +$650K +80,173 +161%
Alyeska Investment Group
24
Alyeska Investment Group
Illinois
$1.73M +$1.01M +125,000 New
HP
25
Hikari Power
Japan
$1.49M – – –
1
2 3 4

ALDX Hedge Fund Activity: Q3 2018 in Review

89 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2018, worth a combined $249M — up 158% from $96.4M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ALDX positions and 8 closed out — a net gain of 23 holders — while 31 added to existing stakes and 13 trimmed.

The largest buyer was Citigroup, adding an estimated $8.27M. The largest seller was Adage Capital Partners, cutting an estimated $2.91M.

  • 89 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2018, up from 66 in Q2 2018.
  • Funds reported $249M of Aldeyra Therapeutics stock for Q3 2018, up 158% quarter-over-quarter.
  • 31 funds opened new Aldeyra Therapeutics positions in Q3 2018 and 8 closed out, a net change of +23 holders.
  • The largest Aldeyra Therapeutics buyer in Q3 2018 was Citigroup, an estimated $8.27M added.
  • The largest Aldeyra Therapeutics seller in Q3 2018 was Adage Capital Partners, an estimated $2.91M sold.

Based on aggregated 13F filings for Q3 2018.